Bristol-Myers Squibb (BMY) Competitors

Johnson & Johnson (NYSE:JNJ) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Which has more volatility and risk, JNJ or BMY?

Johnson & Johnson has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500.

Which has preferable earnings & valuation, JNJ or BMY?

Johnson & Johnson has higher revenue and earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$85.16B	4.33	$35.15B	$6.91	22.16
Bristol-Myers Squibb	$47.44B	2.47	$8.03B	-$3.59	-16.12

Does the MarketBeat Community believe in JNJ or BMY?

Johnson & Johnson received 27 more outperform votes than Bristol-Myers Squibb when rated by MarketBeat users. However, 66.22% of users gave Bristol-Myers Squibb an outperform vote while only 65.16% of users gave Johnson & Johnson an outperform vote.

Company	Underperform	Outperform
Johnson & Johnson	Outperform Votes 1113 65.16%	Underperform Votes 595 34.84%
Bristol-Myers Squibb	Outperform Votes 1086 66.22%	Underperform Votes 554 33.78%

Is JNJ or BMY a better dividend stock?

Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.2%. Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 4.1%. Johnson & Johnson pays out 71.8% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out -66.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 63 consecutive years and Bristol-Myers Squibb has raised its dividend for 16 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Does the media refer more to JNJ or BMY?

In the previous week, Johnson & Johnson had 9 more articles in the media than Bristol-Myers Squibb. MarketBeat recorded 87 mentions for Johnson & Johnson and 78 mentions for Bristol-Myers Squibb. Johnson & Johnson's average media sentiment score of 1.20 beat Bristol-Myers Squibb's score of 0.91 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	65 Very Positive mention(s)	6 Positive mention(s)	13 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Bristol-Myers Squibb	42 Very Positive mention(s)	5 Positive mention(s)	16 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is JNJ or BMY more profitable?

Johnson & Johnson has a net margin of 19.14% compared to Bristol-Myers Squibb's net margin of -15.30%. Johnson & Johnson's return on equity of 35.45% beat Bristol-Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	19.14%	35.45%	14.23%
Bristol-Myers Squibb	-15.30%	11.94%	2.51%

Do analysts prefer JNJ or BMY?

Johnson & Johnson currently has a consensus target price of $175.94, suggesting a potential upside of 14.92%. Bristol-Myers Squibb has a consensus target price of $54.07, suggesting a potential downside of 6.58%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, equities analysts plainly believe Johnson & Johnson is more favorable than Bristol-Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.53
Bristol-Myers Squibb	2 Sell rating(s)	14 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.20

Do institutionals and insiders have more ownership in JNJ or BMY?

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 76.4% of Bristol-Myers Squibb shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Johnson & Johnson beats Bristol-Myers Squibb on 17 of the 22 factors compared between the two stocks.